All In MedTech

Device Trial Radar · NCT02592499

Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure

Swedish Evaluation of Left Ventricular Assist Device

Last checked: Nov 20, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

74

Actual

Start

Jun 2016

Primary completion

Oct 2026

Study completion Dec 2026

Sponsor

Lead sponsor
Vastra Gotaland RegionGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Karolinska University Hospital; University Hospital, Linkoeping; Skane University Hospital; Uppsala University Hospital; University Hospital, Umeå; Region Örebro County
First posted
Oct 30, 2015

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Supportive care
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The study is a prospective, randomized, non-blinded, national, multi-center study. The study will consist of the assignment of eligible patients to treatment with either a HeartMate III (HM III) left ventricular assist device system or to pharmacological treatment (optimal medical management, OMM) according to current guidelines. Eighty (80) patients will be enrolled in this study and randomized in a 1:1 fashion between the HM III and OMM, based on a modified power calculation.

Conditions

  • End-stage Heart Failure

Interventions

  • HM IIIDevice

  • OMM, optimal medical managementOther

    Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Survival at two years of follow-upTime frame: 2 years,

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Sahlgrenska Univesitetssjukhustet, Transplantationscentrum

    Gothenburg, Sweden

  • Linköping Univ Hospital

    Linköping, Sweden

  • Skåne University Hospital

    Lund, Sweden

4 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.